SKP2 and acute lymphoblastic leukemia: Recent research advances demonstrated that SKP2 genetic ablation can delay T-ALL progression in vivo, while the pharmacological blockade of SKP2 can inhibit the proliferation of human T-ALL cells (Rodriguez et al., 2020).